Login to Your Account

Clarity for Cardiome as Merck Returns Rights to Vernakalant

By Catherine Shaffer
Staff Writer

Thursday, September 27, 2012
Six months of uncertainty have come to an end for Cardiome Pharma Corp., as Merck & Co. Inc. announced it would hand global marketing and development rights for I.V. and oral formulations of heart drug vernakalant back to the Vancouver, British Columbia-based company.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription